Mithra Pharmaceuticals SA (1TM.F)

0.1864 +0.0050 (+2.76%) 收市：08:18AM CEST

Mithra Pharmaceuticals SA

Rue Saint-Georges 5
Liège 4000
Belgium
32 4 349 28 22
https://www.mithra.com

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Christophe Marechal	Co-CEO & CFO	無	無	無
Mr. Xavier Paoli M.Sc.	COO & Co-CEO	無	無	無
Dr. Graham K. Dixon Ph.D.	Chief Scientific Officer	無	無	1961
Mr. Alex Sokolowski	Head of Investor Relations	無	無	無
Fanny Rozenberg	Secretary of the Board & General Counsel	無	無	無
Fanny Storms	Compliance Officer	無	無	無
Mr. Frederique Depraetere	Communication Director	無	無	無
Ms. Catherine Lejeune	HR Director	無	無	無
Mr. Jean-Manuel Fontaine	Chief Commercial & External Affairs Officer	無	無	無
Prof. Jean-Michel Foidart M.D., Ph.D.	President of the Scientific Advisory Board & Executive Director	7.12k	無	無

截止 2016年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 EUR。

描述

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.

公司管治

截至 無 止，Mithra Pharmaceuticals SA 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。